Disorder "Ischemic Heart Disease"
Found 8 records
Disorder information
Disorder name:
Ischemic Heart Disease
Disoder ID:
Synonyms:
Heart Disease, Ischemic, IHD, Ischemic Heart Disease, Disease, Ischemic Heart
Definition:
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).
Modifier statisitcs
Record:
8
Gene:
1
Variant:
4
Reference:
1
Effect type:
Expressivity(8)
Modifier effect:
Altered triglyceride level(4)
,Risk factor(4)
| Modifier gene | Variant | Effect type | Modifier effect | Evidence | Effect | PubMed ID |
|---|---|---|---|---|---|---|
| APOC3 | APOC3:A43T | Expressivity | Risk factor | HR=0.64; 95% CI: 0.41 to 0.99; P=0.04 | The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04)more | more |
| APOC3:A43T | Expressivity | Altered triglyceride level | P<0.001 | Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001).more | more | |
| APOC3:c.148G>T(p.Val50Leu) | Expressivity | Risk factor | HR=0.64; 95% CI: 0.41 to 0.99; P=0.04 | The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04)more | more | |
| APOC3:c.148G>T(p.Val50Leu) | Expressivity | Altered triglyceride level | P<0.001 | Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001).more | more | |
| APOC3:c.IVS2+1G>A | Expressivity | Risk factor | HR=0.64; 95% CI: 0.41 to 0.99; P=0.04 | The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04)more | more | |
| APOC3:c.IVS2+1G>A | Expressivity | Altered triglyceride level | P<0.001 | Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001).more | more | |
| APOC3:R19X | Expressivity | Risk factor | HR=0.64; 95% CI: 0.41 to 0.99; P=0.04 | The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04)more | more | |
| APOC3:R19X | Expressivity | Altered triglyceride level | P<0.001 | Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001).more | more |
Total 8,Each Page
,Jump To
Page